India's DMPLOI - Jobs & Networking App
As part of its strategic expansion in specialty care and biopharmaceutical innovation, MS Pharma convened its 1st Annual Biosimilar Summit in Dubai, United Arab Emirates, under the theme “Legacy Illuminated”. The event brought together more than 110 retina specialists from 70 institutions across 15 countries, underscoring MS Pharma’s role as a growing leader in advancing biosimilar science and access in the MENA region.
The summit served as a platform to advance scientific dialogue around the use of biosimilars in ophthalmology, with a particular focus on managing retinal vascular disorders such as diabetic macular edema (DME). Twelve expert-led sessions were delivered by seven international speakers from the United States, UK, France, Switzerland, Italy and India, alongside 27 prominent retina specialists from across the MENA region.
Discussions explored the growing burden of retinal disease, evolving regional treatment practices, and emerging real-world clinical data on the growing role of biosimilars in ophthalmology, highlighting their potential to improve access, reduce treatment burdens, and transform healthcare systems across MENA markets.
“Biosimilars are not just about cost savings, they are about expanding access, elevating standards of care, and reshaping how innovation is delivered across our region. Our Legacy Illuminated summit reflects MS Pharma’s long-term commitment to leading the biosimilar transformation in specialty care and sets a new regional benchmark for scientific collaboration, reinforcing the company’s position as a trusted partner in biopharmaceutical innovation driven by quality, accessibility, and clinical impact,” said Nouha Aissat, Vice President – Specialty Unit at MS Pharma.
The event also marked the launch of a new biosimilar treatment for retinopathies management (Ranibizumab FYB201) by MS Pharma in the GCC region —an important milestone in the company’s ongoing efforts to broaden access to advanced biologic therapies in the region. The launch of this new treatment reinforces MS Pharma’s broader commitment to advancing specialty care through high-quality, cost-effective biosimilar solutions. By addressing critical therapeutic needs in ophthalmology, the company continues to strengthen its position as a regional partner in improving long-term health outcomes.
